ASP Isotopes Targets $300M EBITDA by 2031, Begins 2026 Isotope Shipments
ASP Isotopes expects first commercial shipments of enriched Silicon-28, Carbon-14 and Ytterbium-176 in mid-2026 and to reach Phase 1 helium nameplate capacity of 2,500 GJ/day LNG and 58 MCF/day helium in Q3 2026. The company held $333 million in cash and equivalents at end-2025 and targets more than $300 million EBITDA in 2031.
1. Business Update and Financial Position
ASP Isotopes held $333 million in cash, equivalents and short-term securities as of December 31, 2025 and outlined a path to exceed $300 million EBITDA by 2031. Management emphasized execution across nuclear medicine, electronics and energy platforms and scheduled a business update call for April 13, 2026.
2. Nuclear Medicine Isotopes Production
The Ytterbium-176 plant is on track for initial commercial shipments around mid-2026 following laser repairs, and the Carbon-14 facility expects its final feedstock delivery imminently under a take-or-pay agreement worth $2.5 million annually. These milestones position the company to monetize enriched isotopes in radiopharmaceutical applications.
3. Electronic Gases and Silicon-28
ASP Isotopes has signed three purchase agreements for highly enriched Silicon-28 with major semiconductor and industrial gas firms. After successful sample shipments in late 2025 and collaborative plant enhancements, the first commercial Si-28 shipments are targeted in Q2 2026.
4. Helium and Virginia Gas Project
Following the Renergen acquisition, Phase 1 drilling was completed four months ahead of schedule, delivering well flow rates up to 16× previous levels. Phase 1 nameplate capacity of 2,500 GJ/day LNG and 58 MCF/day liquid helium is expected in Q3 2026, with Phase 2 set to begin construction thereafter.